
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17/07/2014
0:00
7:28
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Mais episódios de "GRACEcast Bladder Cancer Video"



Não percas um episódio de “GRACEcast Bladder Cancer Video” e subscrevê-lo na aplicação GetPodcast.








